A 13-amino-acid peptide mimicking the ACE2 receptor blocked SARS-CoV-2 spike protein binding more effectively at lower doses than a longer 23-amino-acid version.
Shorter = more potentA 13-amino-acid ACE2-derived peptide achieved maximal spike protein inhibition at lower concentrations than a 23-amino-acid version
What the researchers found
Two peptides derived from the ACE2 receptor's α1-helix effectively blocked SARS-CoV-2 spike protein binding. The shorter peptide [30-42] (13 amino acids) achieved maximal inhibition at lower concentrations than the longer peptide [22-44] (23 amino acids), demonstrating that shorter, well-designed peptides can be more potent viral blockers.
Molecular docking models confirmed the experimental findings and identified critical amino acid residues responsible for the inhibitory effect. Both peptides blocked the spike protein's receptor-binding domain residues known to interact with ACE2.
Why it matters
This study demonstrates a peptide-based strategy for blocking viral entry that could serve as a template for antiviral therapeutics. The counterintuitive finding that shorter peptides can be more effective challenges assumptions about peptide drug design and provides a rapid screening methodology (SPR) that could be applied to future pandemic threats.
The numbers in context
2 peptides tested: [30-42] (13 aa) and [22-44] (23 aa) · Shorter peptide more potent · Both blocked ACE2/RBD interaction · SPR + molecular docking validation
How the study worked
In vitro study using surface plasmon resonance (SPR) competitive assays to measure how ACE2-derived peptides inhibit SARS-CoV-2 spike protein binding to the ACE2 receptor. Two peptides of different lengths based on the ACE2 peptidase domain α1-helix were tested. Results were validated with molecular docking simulations to identify critical binding residues.
Who was studied
Not applicable (in vitro biophysical study)
What this study cannot tell us
Entirely in vitro — peptide inhibition of protein-protein interactions on a sensor surface may not translate to blocking viral entry in living cells or organisms. Peptide stability, cell penetration, and bioavailability in vivo were not assessed. COVID-19 variant evolution may affect spike protein binding characteristics.
How to read the evidence
This is an in vitro biophysical study using surface plasmon resonance. While technically rigorous, it tests only molecular binding interactions on a sensor surface — far from demonstrating antiviral efficacy in cells, animals, or humans.
When this study was published
Published in 2023, during the later phase of COVID-19 research. While the immediate urgency of COVID therapeutics has diminished, the peptide design principles and SPR screening methodology remain relevant for future viral threats.
The bigger picture
Peptide-based antivirals offer advantages over antibodies — they're smaller, cheaper to produce, and potentially more adaptable to viral mutations. This work contributes to the growing toolkit of peptide strategies for combating viral infections and establishes a rapid biophysical screening method that could be deployed against future pandemic pathogens.
Questions still open
- Do these ACE2-derived peptides block viral entry in cell-based infection assays?
- How does the shorter peptide's potency hold up against different SARS-CoV-2 variants with mutated spike proteins?
- Could these decoy peptides be delivered as an inhaled nasal spray to prevent viral entry at the site of infection?
Common questions
How could peptides block COVID infection?
Why were shorter peptides better at blocking the spike protein?
Read the original research
Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance.
ACS applied bio materials, 6(1), 182-190
Citation
Abouhajar, Fatimah; Chaudhuri, Rohit; Valiulis, Santino N; Stuart, Daniel D; Malinick, Alexander S; Xue, Min; Cheng, Quan. (2023). Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance.. ACS applied bio materials, 6(1), 182-190. https://doi.org/10.1021/acsabm.2c00832